Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dencatistat - Step Pharma

Next Previous
X
Search
Drug Profile

Dencatistat - Step Pharma

Alternative Names: CTPS1 inhibitor - Step Pharma; STP 938

Latest Information Update: 02 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Step Pharma
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Small molecules
  • Mechanism of Action Cytidine triphosphate synthetase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II B-cell lymphoma; T-cell lymphoma
  • Preclinical Graft-versus-host disease; Inflammation; Rheumatoid arthritis; Solid tumours

Most Recent Events

  • 25 Jun 2024 US FDA approves IND application for Dencatistat for phase-I trial in Solid tumours (PO)
  • 25 Jun 2024 Step Pharma plans a phase-I trial for Solid tumours (Late-stage disease) in September 2024 (PO) (NCT06297525)
  • 30 May 2024 Step Pharma has patent protection for STP 938 in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top